tipifarnib has been researched along with Leukemia, Myeloid, Acute in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (52.94) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, FR; Cooper, BW; Craig, MD; Kaminer, LS; Karp, J; Ketterling, RP; Larson, RA; Lazarus, H; Litzow, MR; Luger, SM; Makary, AZ; Paietta, E; Rowe, JM; Rybka, WB; Tallman, MS; Wang, VX | 1 |
| Blijlevens, N; de Witte, T; Langemeijer, S; Muus, P; van Bijnen, S | 1 |
| Adjei, AA; Ding, H; Flatten, KS; Huang, S; Karp, JE; Kaufmann, SH; Loegering, DA; McDonald, JS; Meng, XW; Oberg, AL; Peterson, KL; Riska, SM; Schneider, PA; Sinicrope, FA; Yun, S | 1 |
| Appelbaum, FR; Erba, HP; Gundacker, HM; Kirschbaum, MH; Kopecky, KJ; Larson, RA; Othus, M; Slovak, ML; Tallman, MS; Walter, RB | 1 |
| Erba, HP | 1 |
| Brandwein, JM; Gupta, V; Howson-Jan, K; Leber, BF; MacAlpine, K; Minden, MD; Moore, M; Schimmer, AD; Schuh, AC; Wright, J; Yee, KW | 1 |
| Adjei, AA; Dai, NT; Feldman, EJ; Flatten, K; Garrett-Mayer, E; Gore, SD; Greer, JM; Ironside, V; Karp, JE; Kaufmann, SH; Le, SB; Levis, MJ; Loegering, DA; Meng, XW; Morris, LE; Ricklis, RM; Ritchie, E; Roboz, G; Schneider, PA; Smith, BD; Talbott, T; Wright, JJ | 1 |
| Gore, SD | 1 |
| Karp, J | 1 |
| de Jonge-Peeters, SD; de Vries, EG; Kuipers, F; van der Weide, K; Vellenga, E | 1 |
| Alexeeva, JA; Bessems, A; Beutel, G; Bordessoule, D; Brandwein, JM; Burnett, AK; De Porre, P; Dombret, H; Golenkov, AK; Harousseau, JL; Howes, AJ; Jedrzejczak, WW; Khuageva, NK; Maertens, J; Martinelli, G; Masszi, T; Mollgard, L; Ossenkoppele, GJ; Park, YC; Robak, T; Thomas, X; Tothova, E; Vidriales, MB | 1 |
| Epling-Burnette, PK; Loughran, TP | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Beaupre, DM; Buzzeo, RW; Cuevas, J; Gabriel, M; Hazlehurst, LA; Mari, Y; Yanamandra, N | 1 |
| Baer, MR; Gojo, I | 1 |
| Forman, SJ; Frankel, P; Karanes, C; Kirschbaum, MH; Newman, EM; O'Donnell, MR; Popplewell, L; Pulone, B; Rincon, A; Stein, AS; Synold, T; Tuscano, J; Wright, J; Zain, JM | 1 |
| Burnett, AK; Hills, RK | 1 |
| Carraway, HE; Derecho, C; Feldman, EJ; Galkin, S; Garret-Mayer, E; Gocke, CD; Gore, SD; Greer, JM; Ironside, V; Karp, JE; Kaufmann, SH; Levis, MJ; Malek, S; McDevitt, MA; Morris, LE; Palma, J; Raponi, M; Ritchie, EK; Roboz, GR; Smith, BD; Vener, TI; Wang, Y; Wright, JJ | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Burnett, AK; Cavanagh, J; Culligan, D; Hills, RK; Kell, J; Milligan, D; Russell, NH; Virchis, A; Wheatley, K | 1 |
| Jawad, M; Pallis, M; Russell, NH; Seedhouse, C; Tandon, K; Yu, N | 1 |
| Karp, JE; Lancet, JE | 1 |
| Cortes, J | 1 |
| Elhamri, M; Thomas, X | 1 |
| Zhang, GS | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Adjei, AA; Bruzek, LM; Feldman, EJ; Garrett-Mayer, E; Gojo, I; Gotlib, J; Greenberg, PL; Greer, J; Karp, JE; Kaufmann, SH; Lancet, JE; Liesveld, JL; Morris, L; Park, Y; Wright, JJ | 1 |
| Atkins, D; Harousseau, JL; Lancet, JE; Löwenberg, B; Rackoff, W; Raponi, M; Stone, R; Wang, Y; Zhang, Y | 1 |
| De Porre, P; Dossey, L; Fan, H; Feldman, EJ; Gojo, I; Gotlib, J; Greenberg, PL; Harousseau, JL; Karp, JE; Lancet, JE; Lee, G; Löwenberg, B; Morris, LE; Raponi, M; Stone, RM; Wang, Y; Wright, JJ | 1 |
| Burnett, AK; Kell, J | 1 |
| Garrett-Mayer, E; Gojo, I; Gore, SD; Greer, J; Karp, JE; Klein, M; Lancet, JE; Levis, MJ; Morris, L; Smith, BD; Wright, JJ | 1 |
| Ange, D; Belly, RT; Bol, K; Buddharaju, L; End, DW; Gojo, I; Highsmith, WE; Hohl, RJ; Horak, I; Karp, JE; Kaufmann, SH; Kottke, TJ; Lancet, JE; Liesveld, J; Rosenblatt, J; Rybak, ME; Thibault, A; Tidwell, ML; Wright, JJ | 1 |
4 review(s) available for tipifarnib and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Topics: Age Factors; Animals; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Quinolones | 2010 |
Farnesyl transferase inhibitors in myeloid malignancies.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myeloid, Acute; Models, Biological; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinolones; ras Proteins; Signal Transduction | 2003 |
[Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Topics: Alkyl and Aryl Transferases; Benzodiazepines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Myeloproliferative Disorders; Piperidines; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; ras Proteins; rho GTP-Binding Proteins | 2005 |
17 trial(s) available for tipifarnib and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quinolones; Salvage Therapy; Survival Rate | 2021 |
A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Quinolones; Treatment Outcome | 2021 |
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid, Acute; Male; Quinolones; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Quinolones; Remission Induction | 2009 |
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Topics: Administration, Oral; Age of Onset; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Quinolones; Tumor Cells, Cultured; U937 Cells | 2009 |
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Neutropenia; Quinolones; Survival Rate; Time Factors | 2009 |
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult | 2011 |
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Recurrence; Risk Factors | 2011 |
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-Binding Proteins; Etoposide; Female; Follow-Up Studies; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Male; Nuclear Proteins; Pharmacogenetics; Prognosis; Quinolones; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2012 |
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolones; Survival Analysis; Treatment Outcome | 2012 |
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quinolones; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2007 |
E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission.
Topics: Aged; Antineoplastic Agents; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Salvage Therapy | 2007 |
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Quinolones; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; DNA-Binding Proteins; Farnesyltranstransferase; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Proportional Hazards Models; Quinolones; Recurrence; Reproducibility of Results; Survival Analysis | 2008 |
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinolones; Remission Induction; Risk Factors; Treatment Outcome | 2008 |
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Bone Marrow; Cohort Studies; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Prenylation; Quinolones; Recurrence; Remission Induction; Treatment Outcome | 2001 |
13 other study(ies) available for tipifarnib and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Monomeric GTP-Binding Proteins; Neuropeptides; Prenylation; Protein Stability; Proto-Oncogene Proteins; Quinolones; Ras Homolog Enriched in Brain Protein; Signal Transduction; TOR Serine-Threonine Kinases; U937 Cells | 2014 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
Topics: Anticholesteremic Agents; Antigens, CD34; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Therapy, Combination; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2009 |
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Cell Membrane; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinolones; Tumor Cells, Cultured; U937 Cells | 2011 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.
Topics: ADP-ribosyl Cyclase 1; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Histones; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Nuclear Proteins; Nucleophosmin; Quinolones; Sialic Acid Binding Ig-like Lectin 3; Signal Transduction | 2012 |
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperidines; Pyridines; Quinolones | 2003 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
Tipifarnib in acute myeloid leukemia.
Topics: Antineoplastic Agents; Controlled Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Quinolones | 2007 |